Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
FAIL · Does not pass the screen
58.61 USD
At the last full screen 2026-09-11
Screened 2026-09-11 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Royalty Pharma plc holds its Markup at $58.61. The statistical read favours the sellers, held for 142 days.
As held on the ledger · 2026-09-11
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 142 days
Price at the screen
$58.61
Valuation
31.51 trailing · 10.22 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.43
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
45.62%
Below 33%
Interest-bearing debt is 45.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
85.62%
Below 33%
Interest-bearing cash and securities are 85.6% of assets, above the one-third limit.
Fail
Receivables
3.30%
Below 49%
Money owed to the company is 3.3% of assets, under the 49% limit.
Pass
Revenue purity
1.41%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 19.4% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +12% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Royalty Deals Offer Safety Without Real Edge
Picture a landlord who owns slices of bestselling medicines rather than bricks and mortar. Royalty Pharma collects payments on thirty five approved drugs plus twenty early stage candidates, delivering 11 percent revenue growth, 34 percent profit margins and 14 percent return on equity at a forward multiple of 10.4 times.
Those figures look solid and the ethical screen clears without issue, yet the opportunity rating sits at none. Our own fair value implies 13 percent upside from the current price, but analyst targets cluster lower and the narrow moat leaves little room for outperformance once key royalties mature.
Patent cliffs and the hit rate on development stage assets remain the real variables. A low multiple on a business like this often signals capped growth rather than hidden value. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RPRX trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-11Markup · changed$62.07+8.4%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 31% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 31% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59.
2026-07-18Markup$54.87+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 31% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 66%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (8 analysts) rates it none, with a mean price target of $59.
2026-07-03Markup$54.87+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$54.87Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.